Bluejay Diagnostics, Inc. (BJDX) Stock Price & Analysis
Bluejay Diagnostics, Inc. (BJDX) fell 13.96% to USD 4.5 as of June 10, 2026 at 01:06 UTC, according to Nexqual real-time market data.
BJDX last closed at USD 5.23; the session ranged USD 4.38–5.59 on volume of 142,685 shares. Market capitalization is $4.66M, with a 52-week range of USD 1.62–16.68 (NCM). Source: Nexqual, June 10, 2026 at 01:06 UTC.
Key Statistics (as of June 10, 2026 at 01:06 UTC)
| Price | USD 4.5 |
|---|---|
| Change | ▼ 13.96% (down) |
| Previous Close | USD 5.23 |
| Open | USD 5.59 |
| Day Range | USD 4.38 – 5.59 |
| 52-Week Range | USD 1.62 – 16.68 |
| Volume | 142,685 shares |
| Market Cap | $4.66M |
| Exchange | NCM |
Technical Analysis (BJDX)
Nexqual's technical model rates BJDX "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 01:06 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 68.87 (neutral) |
| vs SMA50 | Above (USD 2.24) |
| MACD | 0.78 (positive) |
Analyst Ratings (BJDX)
Wall Street analysts rate BJDX "None", per Nexqual as of June 10, 2026 at 01:06 UTC.
| Consensus Rating | None |
|---|
Earnings (BJDX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-12-31 | USD -2,848 vs est -1,360 ▼ miss |
| 2023-09-30 | USD -3,328 vs est -1,344 ▼ miss |
| 2023-06-30 | USD -4,400 vs est -2,240 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:06 UTC.
Financials & Fundamentals (BJDX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -171.56% |
| Debt / Equity | 2.32 |
| Current Ratio | 2.81 |
| Total Cash | $3.68M |
| Total Debt | $97,032 |
| Free Cash Flow | $-4.10M |
Source: Nexqual, June 10, 2026 at 01:06 UTC.
Financial Health Score (BJDX)
Nexqual rates Bluejay Diagnostics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:06 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Critical — ROE -172%, ROA -80.1% |
Ownership (BJDX)
| Insider Ownership | +6.07% |
|---|---|
| Institutional Ownership | +10.62% |
| Shares Outstanding | 1.03M |
| Float | 844,452 |
| Short % of Float | +3.20% |
Source: Nexqual, June 10, 2026 at 01:06 UTC.
Leadership (BJDX)
Bluejay Diagnostics, Inc. is led by Indranil Dey (age 61), Principal Financial, Accounting & Executive Officer, President, CEO and Director, per Nexqual as of June 10, 2026 at 01:06 UTC.
| Principal Financial, Accounting & Executive Officer, President, CEO and Director | Indranil Dey (age 61) |
|---|
Major Backers & Investors (BJDX)
Notable institutional backers of Bluejay Diagnostics, Inc. include Sabby Management, LLC, Fidelity, Tower Research Capital LLC (TRC), according to Nexqual as of June 10, 2026 at 01:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sabby Management, LLC | 2.78% |
| Fidelity | 2.71% |
| Tower Research Capital LLC (TRC) | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 2.72% |
Source: Nexqual, June 10, 2026 at 01:06 UTC.
From Bluejay Diagnostics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Bluejay Diagnostics, Inc. operates as a medical diagnostics company.
- It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.
- The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings.
- In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.23 | ▼ 1.52% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| PRFX | PRF Technologies Ltd. | USD 1.42 | ▼ 10.69% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▼ 0.85% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:06 UTC. This page is informational and not investment advice.